Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
Shirish M GadgeelDelvys Rodríguez-AbreuBalazs HalmosMarina C GarassinoTakayasu KurataYing ChengErin JensenMark ShamounKumar RajagopalanLuis Paz-AresPublished in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024)
gov, NCT02578680 (KEYNOTE-189 global), NCT03950674 (KEYNOTE-189 Japan extension), NCT02775435 (KEYNOTE-407 global), NCT03875092 (KEYNOTE-407 People's Republic of China extension).